A Phase 2b Study to Evaluate the Efficacy, Safety, and PK Profiles of TNP-2092 Administered Via IA Injection in PJI Participants
brief summary
This is a Phase 2b, randomized, controlled, open-label clinical study evaluating the efficacy, safety, and local PK profiles of TNP-2092 administered via IA injection on a background of antibiotic treatment in participants with early postoperative (within 3 months after index arthroplasty) or acute hematogenous (within 4 weeks of infection) PJI after knee arthroplasty, without debridement, and in participants with chronic PJI (including PJI occurring after various joint arthroplasties and revision arthroplasties) requiring long-term antibiotic suppressive treatment.
detailed description
The study population comprises participants with early postoperative (within 3 months of index arthroplasty) or acute hematogenous (within 4 weeks of infection symptoms) PJI after knee arthroplasty, or participants with chronic PJI requiring long-term antibiotic suppressive treatment (including PJI occurring after various joint arthroplasties and revision arthroplasties).
official title
A Phase 2b, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) Profiles of TNP-2092 Administered Via Intra-articular (IA) Injection on a Background of Antibiotic Treatment in Adult Participants With Early Postoperative or Acute Hematogenous Prosthetic Joint Infection (PJI) After Knee Arthroplasty, Without Debridement, or in Participants With Chronic PJI Requiring Long-term Antibiotic Suppressive Treatment.